Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy
Phase 1
Completed
- Conditions
- B-Cell Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2015-03-06
- Last Posted Date
- 2017-06-26
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 26
- Registration Number
- NCT02381080
An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer
Phase 2
Active, not recruiting
- Conditions
- Urothelial Cancer
- Interventions
- First Posted Date
- 2015-02-19
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 239
- Registration Number
- NCT02365597
A Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect After Single Dose Administration of JNJ-54861911 Tablet in Healthy Elderly Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2015-02-04
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 12
- Registration Number
- NCT02355561
Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents Pulmonary MDR-TB
Phase 2
Recruiting
- Conditions
- Multidrug-Resistant Tuberculosis
- Interventions
- Drug: Background Regimen (BR)
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT02354014
- Locations
- 🇿🇦
Sizwe Tropical Diseases Hospital, Johannesburg, South Africa
🇲🇿Hospital Geral da Polana Caniço, Maputo, Mozambique
🇵🇭De La Salle Health Sciences Institute- DLSUMC, Dasmarinas, Philippines
A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
Phase 2
Completed
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Drug: Placebo InfusionDrug: Placebo SCOther: Concomitant Medication
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2020-03-24
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 102
- Registration Number
- NCT02349061
Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
Phase 2
Completed
- Conditions
- Hepatitis C Virus
- Interventions
- First Posted Date
- 2015-01-28
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 68
- Registration Number
- NCT02349048
Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly and and Healthy Younger Adult Participants
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2017-03-03
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 16
- Registration Number
- NCT02345148
A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis
Phase 1
Completed
- Conditions
- Atopic DermatitisAsthmaHealthy
- First Posted Date
- 2015-01-26
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 108
- Registration Number
- NCT02345928
A Study to Evaluate Use of Induced Skin Blisters in Adult Participants With Atopic Dermatitis, Allergic Asthma and Atopic Healthy Participants
Early Phase 1
Completed
- Conditions
- AsthmaHealthyDermatitis, Atopic
- Interventions
- Other: Allergic Skin Reaction (ASR) Testing and Skin Blister Induction
- First Posted Date
- 2015-01-22
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 46
- Registration Number
- NCT02343783
A Study to Evaluate the Absolute Bioavailability of Intranasal and Oral Esketamine and the Effects of Clarithromycin on the Pharmacokinetics of Intranasal Esketamine in Healthy Participants
- First Posted Date
- 2015-01-21
- Last Posted Date
- 2015-09-28
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 18
- Registration Number
- NCT02343289
© Copyright 2025. All Rights Reserved by MedPath